Milestone Scientific Inc. logo

Milestone Scientific Inc.

MLSS

AMEXHealthcareMedical - Instruments & Supplies

Previous close

$0.4808

+$0.0105 · +2.23%

Aug 21, 4:00 PM ET

MLSS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

57

Fair Value

Momentum

48

Neutral

Sentiment

43

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a presence in the United States, China, and other international markets. The company's operations are divided into two main segments: Dental and Medical. Within its Dental division, key products include CompuDent and the STA Single Tooth Anesthesia System, both instrumental for delivering local anesthetics across all dental procedures. For broader applications, the firm offers CompuFlo, a sophisticated computer-controlled system capable of delivering drugs, anesthetics, and other medicaments comfortably and precisely, as well as aspirating bodily fluids or prior injections. Complementing this, a disposable injection handpiece provides precise tactile control during administration. In the Medical segment, Milestone Scientific introduces the CompuFlo Epidural, a computer-guided anesthesia system designed for a variety of medical applications. Additionally, their CompuMed system is utilized in numerous specialized procedures, including plastic surgery, hair restoration, colorectal surgery, podiatry, dermatology, and orthopedics, among others. Headquartered in Livingston, New Jersey, Milestone Scientific Inc. was established in 1989.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Eric C. Hines
Listed since
Nov 3, 1995
Employees
15

Market position

Day range

Current $0.4808

52-week range

Current $0.4808

Open
$0.48
Previous close
$0.4703
Volume
85.69K
0.33× average
Average volume
263.61K
Average daily volume
Market cap
42.53M USD
Beta
1.05
Market reference 1
50-day average
$0.4036
+19.13% above average
200-day average
$0.338
+42.25% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
22.31M USD
EV / EBITDA
-4.05×
Earnings yield
-25.54%
Free cash flow yield
-13.09%

Profitability & efficiency

Return on equity
-203.45%
Return on assets
-73.30%
Return on invested capital
-148.63%

Financial health

Current ratio
1.81×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends92%22%-48%-118%Gross margin, FY2021: 61.25%Gross margin, FY2022: 55.65%Gross margin, FY2023: 69.12%Gross margin, FY2024: 74.56%Gross margin, FY2025: 70.53%Operating margin, FY2021: -71.60%Operating margin, FY2022: -100.24%Operating margin, FY2023: -72.31%Operating margin, FY2024: -78.30%Operating margin, FY2025: -63.48%Net margin, FY2021: -66.17%Net margin, FY2022: -98.87%Net margin, FY2023: -70.51%Net margin, FY2024: -54.62%Net margin, FY2025: -63.76%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 61.25%. Gross margin FY2022 55.65%. Gross margin FY2023 69.12%. Gross margin FY2024 74.56%. Gross margin FY2025 70.53%. Operating margin FY2021 -71.60%. Operating margin FY2022 -100.24%. Operating margin FY2023 -72.31%. Operating margin FY2024 -78.30%. Operating margin FY2025 -63.48%. Net margin FY2021 -66.17%. Net margin FY2022 -98.87%. Net margin FY2023 -70.51%. Net margin FY2024 -54.62%. Net margin FY2025 -63.76%.

Income trends

Revenue

8.97M USD+3.99%

Operating income

−5.7M USD+15.69%

Net income

−5.72M USD-21.40%
Income trends across reported periods12.22M USD4.57M USD−3.09M USD−10.74M USDRevenue, FY2021: 10.3M USDRevenue, FY2022: 8.81M USDRevenue, FY2023: 9.83M USDRevenue, FY2024: 8.63M USDRevenue, FY2025: 8.97M USDOperating income, FY2021: −7.38M USDOperating income, FY2022: −8.83M USDOperating income, FY2023: −7.11M USDOperating income, FY2024: −6.76M USDOperating income, FY2025: −5.7M USDNet income, FY2021: −6.82M USDNet income, FY2022: −8.71M USDNet income, FY2023: −6.93M USDNet income, FY2024: −4.71M USDNet income, FY2025: −5.72M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 10.3M USD. Revenue FY2022 8.81M USD. Revenue FY2023 9.83M USD. Revenue FY2024 8.63M USD. Revenue FY2025 8.97M USD. Operating income FY2021 −7.38M USD. Operating income FY2022 −8.83M USD. Operating income FY2023 −7.11M USD. Operating income FY2024 −6.76M USD. Operating income FY2025 −5.7M USD. Net income FY2021 −6.82M USD. Net income FY2022 −8.71M USD. Net income FY2023 −6.93M USD. Net income FY2024 −4.71M USD. Net income FY2025 −5.72M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue8.97M USD8.63M USD9.83M USD8.81M USD10.3M USD
Cost of goods sold2.64M USD2.2M USD3.03M USD3.91M USD3.99M USD
Gross profit6.33M USD6.43M USD6.79M USD4.9M USD6.31M USD
Research and development449.47K USD858.77K USD701.38K USD1.15M USD878.21K USD
Selling, general, and administrative11.58M USD
Operating expenses12.03M USD13.19M USD13.9M USD13.73M USD13.69M USD
Interest income60.27K USD125.53K USD54.61K USD
Interest expense25.6K USD16.36K USD
Depreciation and amortization185.66K USD37.45K USD62.32K USD63.84K USD73.84K USD
Operating income−5.7M USD−6.76M USD−7.11M USD−8.83M USD−7.38M USD
Net income−5.72M USD−4.71M USD−6.93M USD−8.71M USD−6.82M USD

Company facts updated Aug 24, 2026.

ETFs holding MLSS

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research MLSS

research.disclaimer